PRIMARY BIOSCIENCE, INC.

SEATTLE, WA · Founded 2023 · CIK 0002012695 · Medtech · Private

Ultra-sensitive biosensor chip using nanopatterned surface-enhanced Raman spectroscopy (SERS) for single-molecule protein analysis and post-translational modification detection

primarybioscience.com →
Grants
$305K
1 award
Sector median: 1
Raised
$100K
1 Form D · Oct 2025
12 months since last filing
Contracts
—
No federal contracts on record
Patents
4
0 granted · 4 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · STTR Phase I: Development of an Ultra-Low Concentration Amino Acid Sensor for Use in Protein Sequencing$305,000
Private capital raisedForm D · SEC$100,000
Federal grant · SBIR/STTRForm D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
836HeartBeam, Inc.—$200K
837DL ADV-TECH, LLC——
838LAACClamp Inc.—$150K
839PRIMARY BIOSCIENCE, INC.—$100K
840PENSIEVISION, INC.—$100K
841EndoShunt Medical, Inc.—$75K
842Proteocyte Diagnostics Inc.—$75K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 1 related persons
  • Stacy AndersonDirector · Executive Officer · Promoter

Patents

USPTO · 0 granted of 4
  • Systems And Methods For Analyte Processingapplication
  • System And Method For Peptide Sequencing At Single Molecule Resolutionapplication
  • System And Method For Peptide Sequencing At Single Molecule Resolutionapplication
  • System And Method For Peptide Sequencingapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.